XML 46 R30.htm IDEA: XBRL DOCUMENT

Note 21 - Demadoctor Divestiture and Discontinued Operations

12 Months Ended

Dec. 31, 2024

DERMAdoctor [Member]

Notes to Financial Statements

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

NOTE 21. DERMADOCTOR DIVESTITURE AND DISCONTINUED OPERATIONS

On March 12, 2024, the Company entered into an agreement to sell 100% of the membership units of DERMAdoctor for a closing purchase price of $1.1 million. The sale of the membership units closed, and the DERMAdoctor Divestiture occurred, on March 25, 2024. In order to close the sale, the Company was required to obtain the consent of the holders of the Secured Convertibles Notes (see Note 13, “Convertible Notes”) issued in May 2023 to (i) amend the Security Agreement, dated April 27, 2023 (the “Security Agreement”) to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement and (ii) terminate the Subsidiary Guarantee, dated April 27, 2023 (the “Subsidiary Guarantee”), which DERMAdoctor entered into in connection with the issuance of the Secured Convertible Notes.

On March 24, 2024, the Company and the secured parties entered into a First Amendment to the Security Agreement, (the “First Amendment and Subsidiary Guarantee Consent”) to effect an amendment to the Security Agreement and a Consent and Release to terminate the Subsidiary Guarantee. To obtain the secured parties’ consent and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the secured party’s election, to receive only upon the closing of the DERMAdoctor Divestiture either: a March 2024 Warrant or the Unsecured Convertible Notes (see Note 13 “Convertible Notes”).

The accounting requirements for reporting the DERMAdoctor business as discontinued operations were met during the first quarter of 2024. Accordingly, the consolidated financial statements and notes to the consolidated financial statements reflect the results of the DERMAdoctor business as a discontinued operation for the years presented.

In accordance with the provisions of ASC 205-20, Presentation of Financial Statements: Discontinued Operations (“ASC 205-20”) the Company has separately reported the assets and liabilities of the discontinued operations in the consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the consolidated balance sheets as of December 31, 2023, and consist of the following (in thousands):

		Balance at December 31, 2023

ASSETS
Current assets:
Cash and cash equivalents		$	206
Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023)			79
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)			2,313
Prepaid expenses and other current assets			132
Total current assets, discontinued operations			2,730
Other assets			19
Total assets, discontinued operations		$	2,749

LIABILITIES
Liabilities:
Current liabilities:
Accounts payable		$	224
Accrued liabilities			347
Operating lease liabilities			127
Total current liabilities, discontinued operations			698
Total liabilities, discontinued operations		$	698

In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations. The results of DERMAdoctor’s operations for the years ended December 31, 2024 and 2023 have been reflected as discontinued operations in the consolidated statements of operations and consist of the following (in thousands):

		For the years ended December 31,
		2024				2023
Sales:
Product revenue, net		$	717			$	3,552
Total sales, net			717				3,552

Cost of goods sold			493				2,145
Gross profit			224				1,407
Operating expenses
Research and development			2				34
Sales and marketing			292				1,795
General and administrative			48				883
Goodwill, intangible and other asset impairment			-				2,593
Total operating expenses			342				5,305
Operating loss			(118	)			(3,898	)

Other expense, net			(6	)			(1	)

Net loss from discontinued operations		$	(124	)		$	(3,899	)

In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of cash flows. The results of DERMAdoctor for the years ended December 31, 2024 and 2023 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following (in thousands):

		For the years ended December 31,
		2024				2023

Operating activities:
Net loss from discontinued operations		$	(124	)		$	(3,899	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets			—				152
Impairment of goodwill, intangible and other assets			—				2,595
Non-cash right-of-use amortization			—				112
Changes in operating assets and liabilities:
Accounts receivable			(262	)			237
Inventory			183				429
Prepaid expenses and other current assets			(4	)			162
Other assets			15				(9	)
Accounts payable and accrued liabilities			63				(32	)
Operating lease liabilities			(31	)			(119	)
Net cash used in operating activities, discontinued operations			(160	)			(372	)

Investing activities:
Cash transferred to New Age Investments, LLC			(46	)			—
Purchases of property and equipment			—				(1	)
Net cash used in investing activities, discontinued operations			(46	)			—

Net decrease in cash and cash equivalents, discontinued operations		$	(206	)		$	(373	)